GlassScriptPhysician profile
William E Reynolds
NPI 1134178668
$2,349.77
in general payments reported to CMS, 2019-2025
25 companies · $93.49 in 2025
The $93.49 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2020: $476 · 2021: $42.10 · 2022: $259 · 2023: $230 · 2024: $132 · 2025: $93.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $483.01 | 2019-2024 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $332.40 | 2019-2021 | |
| Astellas Pharma US INC | $276.84 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $236.58 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $202.05 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $126.63 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $94.98 | 2019 | |
| Amgen INC. | $71.01 | 2019-2025 | Evenity |
| Abbvie INC. | $67.96 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.52 | 2019-2024 | Xifaxan, Trulance |
| Allergan, INC. | $57.44 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $49.83 | 2019 | |
| Sunovion Pharmaceuticals INC. | $46.59 | 2019 | |
| Baxter Healthcare | $46.56 | 2020 | |
| Dexcom, INC. | $29.14 | 2023 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $25.17 | 2019 | |
| Lilly USA, LLC | $21.86 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $19.94 | 2020 | |
| Supernus Pharmaceuticals, INC. | $16.70 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.79 | 2020 | |
| Philips North America LLC | $15.16 | 2023 | |
| Amarin Pharma, INC. | $14.79 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.42 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $13.32 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Reynolds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.